Table 1:
Selected clinical studies with novel agents targeting metabolism in RAS-driven cancer
| Diseases | Biomarkers | Therapies | Phase | Study Identifier | Status |
|---|---|---|---|---|---|
| Lung Cancer: Small Cell or Squamous | HRAS, KRAS and NRAS mutations in Codons 12, 13, 61, 117, and 146 | Auranofin and Sirolimus | Phase 1/Phase 2 | NCT01737502 | Recruiting |
| Metastatic Pancreatic Carcinoma, Stage II, III, IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma | MEK | Trametinib, Hydroxychloroquine | Phase 1 | NCT03825289 | Recruiting |
| Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer | KRAS Mutation | Hydroxychloroquine, Binimetinib | Phase 1 | NCT04132505 | Recruiting |
| Lung Cancer: Non-Small Cell Lung Carcinoma | KRAS Mutation | CB-839, Docetaxel | Phase 1 | NCT02071862 | Completed |
| Colon Carcinoma | KRAS and BRAF mutation | Carbohydrate-Restricted Diet, Vitamin C Supplement | Phase 1/Phase 2 | NCT04035096 | Not yet recruiting |
| Metastatic Melanoma | NRAS Mutation | Trametinib, Hydroxychloroquine | Phase 1b/Phase 2 | NCT03979651 | Recruiting |
| Non-Small Cell Lung Carcinoma, Colorectal Carcinoma | KRAS Mutation | CB-839, Palbociclib | Phase 1/Phase 2 | NCT03965845 | Recruiting |
| Gastrointestinal Adenocarcinomas | MAPK mutations: KRAS, NRAS, HRAS, BRAF non-V600, MEK, and ERK mutations |
Ulixertinib, Hydroxychloroquine | Phase 1 | NCT04145297 | Recruiting |
| Pancreatic Cancer: Metastatic Adenocarcinoma | Mutant KRAS | Hydroxychloroquine, Gemcitabine | Phase 1/Phase 2 | NCT01506973 | Active, not recruiting |
| Non-squamous Cell Lung Cancer | Wild type and mutant KRAS | AZD2014, AZD6244 | Phase 1/Phase 2 | NCT02583542 | Active, not recruiting |
| Colon Cancer | KRAS, BRAF Mutation status | TVB-2640 | Phase 1 | NCT02980029 | Recruiting |
| Breast Cancer, Endometrial Cancer, Lung Cancer, Colorectal Cancer, Head and Neck Cancer | KRAS mutations | Serabelisib, Canagliflozin | Phase 1/Phase 2 | NCT04073680 | Not yet recruiting |
| Metastatic Colorectal Cancer | RAS Wild Type | CB-839, Panitumumab, Irinotecan | Phase 1/Phase 2 | NCT03263429 | Recruiting |
| Colorectal Cancer | RAS Wild Type | BAY94–9392, 11C-Glutamine | Phase 1 | NCT03275974 | Recruiting |
According to My Cancer Genome and ClinicalTrials.gov database